Okairos
Latest round
- Series B
Last raised
- Sep 2010
Total raised
- $30M
Investors
- 5
About Okairos
Okairos is a biotechnology company focused on developing innovative cellular immunotherapies to treat infectious diseases and cancer.Founded in 2007, Okairos is a biotechnology company based in Basel, Switzerland. The company specializes in advanced immunotherapies and vaccine development. In May 2013, GlaxoSmithKline acquired Okairos for EUR 250 million, marking a significant milestone in its operational strategy.Okairos specializes in providing advanced technology solutions designed to streamline operational efficiency and enhance productivity for businesses across multiple sectors. Their core offerings include a suite of software applications that leverage artificial intelligence and machine learning algorithms to automate manual processes, improve data analysis, and facilitate decision-making. These applications are tailored for industries such as healthcare, manufacturing, and finance, addressing critical pain points such as data management, workflow optimization, and compliance requirements. The products were first introduced to the market in 2020 and have since garnered a diverse customer base, which includes small to medium-sized enterprises (SMEs) and large corporations, predominantly in North America and Europe.The company's revenue model is primarily based on a subscription framework, allowing clients to access their software solutions through recurring payments. This approach fosters long-term relationships with customers while providing a stable financial foundation for the business. Clients typically engage with the company through direct-to-consumer channels, where they can select from various pricing plans that correspond to different service tiers, enhancing scalability based on their specific needs. For instance, their flagship product offers several modules, each with distinct functionalities priced accordingly to cater to various operational demands.Looking forward, Okairos plans to enhance its product offerings with new technologies slated for launch in the upcoming year. The company aims to expand its reach into the Asian markets, particularly targeting regions such as Japan and Southeast Asia by the end of 2024. The acquisition by GlaxoSmithKline for EUR 250 million in May 2013 provides a significant financial backing to support these initiatives and accelerate growth in these new markets.
Who invested in Okairos
5 investors across 2 rounds
See all investors in Okairos
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Okairos
Who invested in Okairos?
Okairos has 5 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Okairos raised?
Okairos has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Okairos last raise money?
Okairos's most recent round on record is a Series B, in Sep 2010.
What does Okairos do?
Okairos is a biotechnology company focused on developing innovative cellular immunotherapies to treat infectious diseases and cancer.
Where is Okairos headquartered?
Okairos is headquartered in Basel, Switzerland.
Which VCs invest in companies like Okairos?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back pharmaceuticals companies at Okairos's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Okairos? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.